Literature DB >> 32174708

Drug-containing hydrophobic dressings as a topical experimental therapy for cutaneous leishmaniasis.

Viviane Pereira1,2, Neuza Biguinati de Barros1, Sharon Rose Aragão Macedo1, Amália Dos Santos Ferreira1, Luiz Alberto Kanis3, Roberto Nicolete1,4.   

Abstract

Cutaneous leishmaniasis (CL), a clinical condition caused mainly by Leishmania amazonensis in Brazil, is characterized by topical, painless ulcers. The current treatment, based on intravenous administration of pentavalent antimonials, presents low adherence by patients and may cause serious adverse effects, leading to the need for searching new therapeutic options. Thus, this study aimed at evaluating a topical administration of "intelligent dressings" as an alternative treatment for CL. BALB/c mice were infected with L. amazonensis promastigotes. Afterward, lesions were treated with hydrophobic dressings incorporated with clinically used drugs. After lesion development, the following analyses were carried out: measurement of lesion diameters, biochemical analyses of serum, evaluation of the recovery of amastigote forms and histological analyses. No significant clinical changes in serum parameters were observed. The group that was treated with dressings impregnated with Glucantime® displayed the lowest number of amastigotes recovered from tissues (parasite load). Conventional treatment with Glucantime® (i.p.) was also able to reduce parasite load. After 6 weeks from the measurement of the lesions mice treated with dressings impregnated with Pentamidine displayed the smallest values. Representative histological aspects of the lesions showed the absence or few amastigotes inside the macrophages when mice were treated with dressings impregnated with Glucantime® and Pentamidine, respectively. The findings presented here indicate that the topical treatments may constitute an alternative treatment option for CL. © Indian Society for Parasitology 2019.

Entities:  

Keywords:  Antileishmanial drugs; Cutaneous leishmaniasis; Hydrophobic “intelligent” bandage aid; Topical treatment

Year:  2019        PMID: 32174708      PMCID: PMC7046828          DOI: 10.1007/s12639-019-01162-y

Source DB:  PubMed          Journal:  J Parasit Dis        ISSN: 0971-7196


  18 in total

Review 1.  Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.

Authors:  Simon L Croft; Graham H Coombs
Journal:  Trends Parasitol       Date:  2003-11

2.  Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis.

Authors:  Tracy Garnier; Antti Mäntylä; Tomi Järvinen; M Jayne Lawrence; Marc B Brown; Simon L Croft
Journal:  J Pharm Pharmacol       Date:  2007-01       Impact factor: 3.765

Review 3.  Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

Authors:  François Chappuis; Shyam Sundar; Asrat Hailu; Hashim Ghalib; Suman Rijal; Rosanna W Peeling; Jorge Alvar; Marleen Boelaert
Journal:  Nat Rev Microbiol       Date:  2007-11       Impact factor: 60.633

Review 4.  Clinical status of agents being developed for leishmaniasis.

Authors:  Jonathan Berman
Journal:  Expert Opin Investig Drugs       Date:  2005-11       Impact factor: 6.206

5.  Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica.

Authors:  M Solomon; F Pavlotsky; E Leshem; M Ephros; H Trau; E Schwartz
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-12-05       Impact factor: 6.166

Review 6.  Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.

Authors:  Luiz F Oliveira; Armando O Schubach; Maria M Martins; Sônia L Passos; Raquel V Oliveira; Mauro C Marzochi; Carlos A Andrade
Journal:  Acta Trop       Date:  2011-03-21       Impact factor: 3.112

7.  MOLECULAR CHARACTERIZATION OF AMERICAN CUTANEOUS LEISHMANIASIS IN THE TRI‑BORDER AREA OF ASSIS BRASIL, ACRE STATE, BRAZIL.

Authors:  Carolina Bioni Garcia Teles; Jansen Fernandes Medeiros; Ana Paula de Azevedo dos Santos; Luís Antônio Rodrigues de Freitas; Tony Hiroshi Katsuragawa; Lilian Motta Cantanhêde; Ricardo de Godoi Mattos Ferreira; Luís Marcelo Aranha Camarg
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 Jul-Aug       Impact factor: 1.846

8.  DETC-based bacterial cellulose bio-curatives for topical treatment of cutaneous leishmaniasis.

Authors:  Fabiana S Celes; Eliane Trovatti; Ricardo Khouri; Johan Van Weyenbergh; Sidney J L Ribeiro; Valeria M Borges; Hernane S Barud; Camila I de Oliveira
Journal:  Sci Rep       Date:  2016-12-06       Impact factor: 4.379

9.  Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice.

Authors:  Danilo C Miguel; Jenicer K U Yokoyama-Yasunaka; Silvia R B Uliana
Journal:  PLoS Negl Trop Dis       Date:  2008-06-11

10.  Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre.

Authors:  Rosiana Estéfane da Silva; Antonio Toledo; Maria Camilo Senna; Ana Rabello; Gláucia Cota
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-08       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.